Day: June 26, 2024

Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer LOS ALTOS, Calif., June 26, 2024 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that the University of Nebraska Medical Center (UNMC) is now enrolling patients with Locally Advanced Pancreatic Cancer (LAPC) in the Company’s ongoing pivotal Phase III TIGeR-PaC clinical trial. The TIGeR-PaC study is using RenovoRx’s patented TAMP (Trans-Arterial Micro-Perfusion) therapy platform to evaluate its RenovoGem investigational drug-device combination product. RenovoGem utilizes pressure-mediated delivery of chemotherapy across the arterial wall to bathe tumor tissue. The...

Designed to celebrate the rich and diverse culture of Singapore Reports successful launch with plans to rapidly expand Company’s own branded products within the multi-billion-dollar global gift market Singapore, June 26, 2024 (GLOBE NEWSWIRE) —  Webuy Global Ltd. (Nasdaq: WBUY) (“Webuy” or the “Company”), a Southeast Asian community e-commerce retailer, today announced the launch of its Sing Select gift series, a new line of high-quality, thoughtfully curated gift sets designed to celebrate the rich and diverse culture of Singapore. The series was officially launched in May 2024 with the Plum Wine Gift Set as the first proprietary product in the series. Consumer demand for the Plum Wine Gift Set has exceeded expectations, with more than 700 sets sold in a single day. Building on the initial success of the Plum Wine Gift Set, Webuy...

Trading to Continue Under Same Ticker Symbol OMQS Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) — OMNIQ Corp. (OTC PINK: OMQS) (“OMNIQ” or “the Company”), a leading provider of Artificial Intelligence (AI)-based solutions for supply chain management and data processing, today announced that its stock has transitioned from NASDAQ to the OTC Markets. OMNIQ’s stock continues to trade under the ticker symbol OMQS, ensuring uninterrupted market activity for its shareholders. OMNIQ remains committed to maintaining the highest standards of corporate governance and transparency. Nasdaq determination to delist the company’s stock, effective May 7, 2024, is due to not meeting the minimum market value requirement of $35 million. OMNIQ remains fully compliant with all other regulatory guidelines and is actively taking steps to be relisted...

VANCOUVER, BC, June 26, 2024 (GLOBE NEWSWIRE) — AMERICAN SALARS LITHIUM INC. (“AMERICAN SALARS” OR THE “COMPANY”) (CSE: USLI, OTC: ASALF, FWB: Z3P, WKN: A3E2NY) announces it has received confirmation that the ALS Geochemistry Laboratory in Reno Nevada has received 121 samples collected from the Company’s 100% owned Black Rock South Lithium Brine Project, located 11 miles north of the “Galt” claim group under option to Surge Battery Metals (CSE: NILI). Samples will be processed using Boyd RSD rotary crushers and splitter with a 180-micron (80 mesh) sieve, aqua regia digestion, and 41 multi-element ICP-AES analysis (code ME-ICP41). Black Rock South Highlights58 soil samples were collected across and around the Black Rock South property Land Research was completed in the vicinity of the property 63 prospecting...

These C-Bond BRS installations will be completed by trained local installers in C-Bond’s growing dealer network, which includes 50 dealers SAN ANTONIO, June 26, 2024 (GLOBE NEWSWIRE) — C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a developer and marketer of glass strengthening solutions for enhanced safety, today announced that its Patriot Glass Solutions subsidiary continues to broaden its geographic reach with two new purchase orders to install C-Bond BRS (ballistic-resistant system) at a United Services Automobile Association (USAA) location in North Carolina and a courthouse in Oklahoma. Patriot Glass Solutions will custom-cut the ballistic-resistant film and the installations will be completed by trained local film installers in C-Bond’s growing dealer network, which now includes 50 dealers. C-Bond BRS is a ballistic-resistant...

WILMINGTON, Mass., June 26, 2024 (GLOBE NEWSWIRE) — UniFirst Corporation (NYSE: UNF) (the “Company,” “UniFirst” or “we”) today reported results for its third quarter ended May 25, 2024 as compared to the corresponding period in the prior fiscal year: Q3 2024 Financial HighlightsConsolidated revenues for the third quarter increased 4.6% to $603.3 million. Operating income was $48.5 million, an increase of 45.1%. The quarterly tax rate decreased to 22.9% compared to 27.2% in the prior year. Net income increased to $38.1 million from $24.3 million in the prior year, or 56.8%. Diluted earnings per share increased to $2.03 from $1.29 in the prior year, or 57.4%. EBITDA increased to $82.5 million compared to $64.0 million in the prior year, or 29.0%. Cash flow from operating activities increased to $193.0 million in the first nine...

Belships has declared a purchase option for BELMAR, which has been leased since its delivery as a newbuilding in 2021. The purchase price is USD 25.5m and the vessel will be taken over in Q4 2024. The acquisition will be financed from the company’s available cash. Furthermore, Belships has agreed to acquire a Japanese-built Ultramax of 64 000 dwt built in 2024 from an unrelated party. The purchase price is USD 41.0m and the vessel will be delivered within Q1 2025. The intention is to utilise our available Accordian Tranche which implies financing for 60 per cent of the purchase price and the remaining will be financed from the company’s available cash. The sale of the two Supramax vessels BELFRIEND and BELTIDE announced previously are expected to be handed over to their new owners within Q3 2024. As the vessels are free of debt the sales...

Meriaura Group Plc Company Announcement            26 June 2024 at 2.00 p.m. (CEST)Meriaura Group Plc – Managers’ Transaction, Jussi Mälkiä, June 2024   Person subject to the notification requirementName: Meriaura Invest Oy  Position: Closely associated person(x) Legal Person (1): Associated PersonName Mälkiä, Jussi-PekkaPosition Member of the Board/Deputy member  Initial Notification  Reference number: 67381/4/4     IssuerName: Meriaura Group PlcLEI: 743700J1YZ8IEJAPDL21     Transaction detailsTransaction date: 2024-06-25Venue: Outside a trading venueNature of the transaction: ACQUISITIONFurther details:   Instrument: SHAREISIN: FI4000425848 (1) Volume: 6800000Unit price: 0.05882 EUR(2) Volume: 6800000Unit price: 0.05882 EUR Aggregated transactionsVolume: 13600000Volume...

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) — via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), announces the filing of the new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023. This patent covers novel crystalline forms of buntanetap and their use for treating and/or preventing various neurodegenerative conditions. Crystalline forms offer significant advantages over less structured forms, including better solubility and stability. The most stable crystal form of buntanetap (CAS# 3032752-92-1)...

Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and are admitted to the intensive care unit (ICU). ACTON, Mass., June 26, 2024 (GLOBE NEWSWIRE) — Bluejay Diagnostics, Inc. (NASDAQ: BJDX), today announced results from the primary analysis of SYMON-I, a multicenter pilot clinical study investigating the role of interleukin-6 (IL-6) in patients diagnosed with sepsis and septic shock. This prospective study assessed the utility of IL-6 upon initial presentation to the intensive care unit (ICU). The primary analysis of the SYMON-I study (registered clinical trial number NCT06181604) highlighted that IL-6 levels within 24 hours of sepsis or septic shock diagnosis and admission to the ICU may...